Johnson & Johnson (NYSE:JNJ) Shares Sold by Fifth Third Bancorp

Fifth Third Bancorp trimmed its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 3.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,281,478 shares of the company's stock after selling 40,071 shares during the quarter. Johnson & Johnson makes up 0.8% of Fifth Third Bancorp's investment portfolio, making the stock its 26th largest position. Fifth Third Bancorp owned approximately 0.05% of Johnson & Johnson worth $202,717,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. McAdam LLC raised its holdings in shares of Johnson & Johnson by 3.2% in the 1st quarter. McAdam LLC now owns 6,166 shares of the company's stock valued at $975,000 after purchasing an additional 194 shares in the last quarter. Wesbanco Bank Inc. grew its position in shares of Johnson & Johnson by 5.0% in the 1st quarter. Wesbanco Bank Inc. now owns 226,777 shares of the company's stock valued at $35,874,000 after buying an additional 10,746 shares during the last quarter. Summit Trail Advisors LLC grew its position in shares of Johnson & Johnson by 90.7% in the 1st quarter. Summit Trail Advisors LLC now owns 35,131 shares of the company's stock valued at $5,557,000 after buying an additional 16,713 shares during the last quarter. Regatta Capital Group LLC grew its position in shares of Johnson & Johnson by 1.4% in the 1st quarter. Regatta Capital Group LLC now owns 5,849 shares of the company's stock valued at $925,000 after buying an additional 81 shares during the last quarter. Finally, Stablepoint Partners LLC grew its position in shares of Johnson & Johnson by 19.8% in the 1st quarter. Stablepoint Partners LLC now owns 30,813 shares of the company's stock valued at $4,874,000 after buying an additional 5,090 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Shares of JNJ stock traded down $0.65 during mid-day trading on Friday, reaching $149.27. The stock had a trading volume of 6,532,718 shares, compared to its average volume of 8,672,784. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $175.97. The company has a market cap of $359.25 billion, a P/E ratio of 9.31, a price-to-earnings-growth ratio of 2.47 and a beta of 0.55. The business has a 50-day simple moving average of $154.19 and a 200 day simple moving average of $155.02. The company has a current ratio of 1.17, a quick ratio of 0.91 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating analysts' consensus estimates of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The business had revenue of $21.38 billion during the quarter, compared to analysts' expectations of $21.39 billion. During the same quarter last year, the business posted $2.68 earnings per share. The business's revenue for the quarter was up 2.3% on a year-over-year basis. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.32%. The ex-dividend date of this dividend is Monday, May 20th. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.19. Johnson & Johnson's dividend payout ratio (DPR) is currently 29.68%.

Analyst Ratings Changes

A number of research firms recently commented on JNJ. Bank of America dropped their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 17th. HSBC raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating and increased their target price for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, February 6th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Monday, April 15th. Finally, Morgan Stanley lowered their price target on Johnson & Johnson from $168.00 to $167.00 and set an "equal weight" rating on the stock in a report on Wednesday, April 17th. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $175.86.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares of the company's stock, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.